Afatinib (BIBW2992)

Catalog No.S1011

Molecular Weight(MW): 485.94

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.

Cited by 175 Publications

Nature, 2019, 571(7763):127-131

PubMed: 31243371 ( click the link to review the publication )

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cancer Discov, 2019, 9(7):926-943

PubMed: 31092401 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(5):638-646

PubMed: 29686424 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nat Med, 2017, 23(10):1167-1175

PubMed: 28920960 ( click the link to review the publication )

Nature, 2016, 534(7609):647-51

PubMed: 27338794 ( click the link to review the publication )

Cancer Discov, 2015, 5(7):713-22

PubMed: 25934077 ( click the link to review the publication )

Cancer Discov, 2013, 3(2):168-81

PubMed: 23229345 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Oncogene, 2019, 38(30):5890-5904

PubMed: 31253872 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):282

PubMed: 31262325 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):266

PubMed: 31215502 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)

PubMed: 31181806 ( click the link to review the publication )
Cell Death Dis, 2019, 10(9):663

PubMed: 31506424 ( click the link to review the publication )

Br J Cancer, 2019, 121(10):846-856

PubMed: 31607750 ( click the link to review the publication )

Cancers (Basel), 2019, 11(2)

PubMed: 30736342 ( click the link to review the publication )

Cells, 2019, 8(12)

PubMed: 31795298 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(4):733-742

PubMed: 30787176 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):920-928

PubMed: 30872380 ( click the link to review the publication )

J Cancer, 2019, 10(9):2063-2073

PubMed: 31205567 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(6):1282-1292

PubMed: 31285959 ( click the link to review the publication )

Oncogenesis, 2019, 8(10):54

PubMed: 31570699 ( click the link to review the publication )

Mol Cancer Res, 2019, 17(11):2233-2243

PubMed: 31467113 ( click the link to review the publication )

Gynecol Oncol, 2019, 153(1):158-164

PubMed: 30630630 ( click the link to review the publication )

J Cell Physiol, 2019, 10.1002/jcp.28881

PubMed: 31152452 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3584-3594

PubMed: 31446643 ( click the link to review the publication )

Clin Lung Cancer, 2019, 20(3):167-177

PubMed: 30885551 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4488-4497

PubMed: 30679314 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 10.1038/s41401-019-0248-2

PubMed: 31171828 ( click the link to review the publication )

Front Physiol, 2019, 10:189

PubMed: 30971932 ( click the link to review the publication )

Cancer Res Treat, 2019, 51(3):951-962

PubMed: 30309221 ( click the link to review the publication )

Transl Oncol, 2019, 12(6):852-858

PubMed: 31030101 ( click the link to review the publication )

Oncol Rep, 2019, 41(2):1059-1066

PubMed: 30483795 ( click the link to review the publication )

Clin Otolaryngol, 2019, 10.1111/coa.13434

PubMed: 31536667 ( click the link to review the publication )

Mol Med Rep, 2019, 20(4):3317-3325

PubMed: 31432165 ( click the link to review the publication )
Pharmaceuticals (Basel), 2019, 12(4)

PubMed: 31703435 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 8(1):37-60

PubMed: 30836148 ( click the link to review the publication )

Oncotarget, 2019, 10(14):1440-1457

PubMed: 30858928 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Nat Struct Mol Biol, 2018, 25(6):454-462

PubMed: 29760531 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(11):2594-2604

PubMed: 29298799 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Genes Dev, 2018, 32(17-18):1201-1214

PubMed: 30143526 ( click the link to review the publication )

Cancer Immunol Res, 2018, 6(12):1511-1523

PubMed: 30242021 ( click the link to review the publication )

Theranostics, 2018, 8(12):3176-3188

PubMed: 29930721 ( click the link to review the publication )

Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Oncogene, 2018, 37(12):1576-1593

PubMed: 29326440 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

EBioMedicine, 2018, 29:112-127

PubMed: 29433983 ( click the link to review the publication )

Cancers (Basel), 2018, 10(6)

PubMed: 29925812 ( click the link to review the publication )

Cancer Discov, 2018, 8(9):1087-1095

PubMed: 29802158 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1648-1658

PubMed: 29748209 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2144-2155

PubMed: 30065098 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(9):2024-2033

PubMed: 29959202 ( click the link to review the publication )

Mol Oncol, 2018, 12(6):830-854

PubMed: 29603584 ( click the link to review the publication )

Mol Oncol, 2018, 12(4):441-462

PubMed: 29325228 ( click the link to review the publication )

Cancer Sci, 2018, 109(11):3657-3661

PubMed: 30255614 ( click the link to review the publication )
Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Front Oncol, 2018, 8:432

PubMed: 30345256 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(42):16518-16527

PubMed: 30166343 ( click the link to review the publication )

Am J Cancer Res, 2018, 8(8):1541-1550

PubMed: 30210922 ( click the link to review the publication )

Ann Thorac Surg, 2018, 105(2):363-370

PubMed: 29223420 ( click the link to review the publication )

Int J Oncol, 2018, 53(4):1544-1556

PubMed: 30066854 ( click the link to review the publication )

Invest New Drugs, 2018, 36(6):999-1005

PubMed: 29594878 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Biosci Rep, 2018, 38(6)

PubMed: 30420490 ( click the link to review the publication )

Onco Targets Ther, 2018, 11:8201-8209

PubMed: 30568455 ( click the link to review the publication )

J Craniomaxillofac Surg, 2018, 46(3):492-497

PubMed: 29311018 ( click the link to review the publication )

Bladder Cancer, 2018, 4(1):77-90

PubMed: 29430509 ( click the link to review the publication )

Oncotarget, 2018, 9(9):8560-8572

PubMed: 29492217 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Nat Commun, 2017, 8:13897

PubMed: 28059068 ( click the link to review the publication )

Elife, 2017, 10.7554/eLife.25946

PubMed: 28598329 ( click the link to review the publication )

Oncogene, 2017, 36(13):1873-1886

PubMed: 27694893 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Cell Death Dis, 2017, 8(5):e2773

PubMed: 28492539 ( click the link to review the publication )

Neoplasia, 2017, 19(12):1012-1021

PubMed: 29136529 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )
Sci Rep, 2017, 7:44089

PubMed: 28276478 ( click the link to review the publication )

Cancer Prev Res, 2017, 10(1):76-88

PubMed: 27756753 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2017, 335:16-27

PubMed: 28942004 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 491(3):656-661

PubMed: 28756224 ( click the link to review the publication )

Oncol Lett, 2017, 14(4):4349-4354

PubMed: 28959367 ( click the link to review the publication )

Oncotarget, 2017, 8(3):4277-4288

PubMed: 28032592 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017, 8(38):63901-63910

PubMed: 28969039 ( click the link to review the publication )

Oncotarget, 2017, 8(35):58771-58780

PubMed: 28938595 ( click the link to review the publication )

BMB Rep, 2017, 50(3):150-155

PubMed: 28256196 ( click the link to review the publication )

Gut, 2016, 1296-305

PubMed: 26001389 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Expert Opin Drug Deliv, 2016, 13(1):133-41

PubMed: 26371512 ( click the link to review the publication )

Mol Pharm, 2016, 13(6):2117-25

PubMed: 27169328 ( click the link to review the publication )

Am J Cancer Res, 2016, 6(8):1708-19

PubMed: 27648360 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0146311

PubMed: 26735495 ( click the link to review the publication )

Mol Med Rep, 2016, 13(3):2338-44

PubMed: 26782932 ( click the link to review the publication )

Oncotarget, 2016, 7(28):42859-42872

PubMed: 27374095 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58038-58050

PubMed: 27487128 ( click the link to review the publication )
Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016, 7(26):40398-40417

PubMed: 27259258 ( click the link to review the publication )

Oncotarget, 2016, 7(50):83424-83436

PubMed: 27825137 ( click the link to review the publication )

Gut, 2015, 10.1136/gutjnl-2014-309026

PubMed: ( click the link to review the publication )

Nat Commun, 2015, 6:8481

PubMed: 26412466 ( click the link to review the publication )

J Thorac Oncol, 2015, 10(1):93-101

PubMed: 25384171 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2789

PubMed: 25948633 ( click the link to review the publication )

Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-15-0560

PubMed: 25964297 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4597-606

PubMed: 26138066 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Mol Cancer Ther, 2015, 14(1):298-306

PubMed: 25344583 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(2):1088-99

PubMed: 25487801 ( click the link to review the publication )

Drug Metab Dispos, 2015, 43(3):375-84

PubMed: ( click the link to review the publication )

Cell Tissue Res, 2015, 359(3):799-816

PubMed: ( click the link to review the publication )

Oncol Rep, 2015, 34(6):2864-70

PubMed: 26503698 ( click the link to review the publication )

Oncol Rep, 2015, 34(6):2864-70

PubMed: 26503698 ( click the link to review the publication )

Arch Immunol Ther Exp, 2015, 10.1007/s00005-015-0330-5

PubMed: 25678473 ( click the link to review the publication )

PLoS One, 2015, 10(4):e0123623

PubMed: 25853726 ( click the link to review the publication )

Anticancer Res, 2015, 35(4):2005-8

PubMed: 25862853 ( click the link to review the publication )

J Anal Methods Chem, 2015, 2015:215128

PubMed: 26101692 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Nat Commun, 2014, 5:5232

PubMed: 25366117 ( click the link to review the publication )
J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(21):5423-34

PubMed: 25189483 ( click the link to review the publication )

Cancer Res, 2014, 74(1):341-52

PubMed: 24177178 ( click the link to review the publication )

Oncogene, 2014, 33(25):3334-41

PubMed: 23873022 ( click the link to review the publication )

Anal Chem, 2014, 86(21):10568-75

PubMed: 25263480 ( click the link to review the publication )

Br J Cancer, 2014, 111(9):1750-6

PubMed: 25268372 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(9):1239-47

PubMed: 24971884 ( click the link to review the publication )

Histochem Cell Biol, 2014, 142(4):361-71

PubMed: 24824474 ( click the link to review the publication )

Target Oncol, 2014, 10.1007/s11523-014-0344-7

PubMed: 25341405 ( click the link to review the publication )

Oncotarget, 2014, 5(21):10503-17

PubMed: 25361177 ( click the link to review the publication )

Genes Cancer, 2014, 5(7-8):261-72

PubMed: 25221644 ( click the link to review the publication )

Oncotarget, 2014, 5(24):12877-90

PubMed: 25375092 ( click the link to review the publication )

Drug Metab Lett, 2014, 8(1):19-30

PubMed: 24628405 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(10):972-7

PubMed: 25173978 ( click the link to review the publication )

Oncotarget, 2014, 5(15):5908-19

PubMed: 25115383 ( click the link to review the publication )

Sci Transl Med, 2013, 5(199):199ra111

PubMed: 23966300 ( click the link to review the publication )

Eur J Cancer, 2013, 49(6):1458-66

PubMed: 23153706 ( click the link to review the publication )

Oncogene, 2013, 32(37):4427-35

PubMed: 23045273 ( click the link to review the publication )

Cancer Sci, 2013, 104(5):584-9

PubMed: 23387505 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Cancer Biol Ther, 2013, 14(6):537-45

PubMed: 23760496 ( click the link to review the publication )

PLoS One, 2013, 8(12):e84700

PubMed: 24386407 ( click the link to review the publication )

PLoS One, 2013, 8(2):e56567

PubMed: 23451056 ( click the link to review the publication )
Evid Based Complement Alternat Med, 2013, 2013:243859

PubMed: 23533466 ( click the link to review the publication )

J Thorac Oncol, 2012, 7(2):272-80

PubMed: 22089117 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(6):1663-71

PubMed: 22317763 ( click the link to review the publication )

Cancer Res Treat, 2012, 44(3):202-9

PubMed: 23091447 ( click the link to review the publication )

PLoS One, 2012, 7(7):e41017

PubMed: 22815900 ( click the link to review the publication )

Oncol Res, 2011, 19(10-11):471-8

PubMed: 22715590 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively.

Targets

EGFR (L858R) ^[1] (Cell-free assay)	EGFR (wt) ^[1] (Cell-free assay)	ErbB4 ^[2] (Cell-free assay)	EGFR (L858R/T790M) ^[1] (Cell-free assay)	HER2 ^[1] (Cell-free assay)
0.4 nM	0.5 nM	1 nM	10 nM	14 nM

In vitro

BIBW2992 shows potent activity against both wild-type and mutant forms of EGFR and HER2. It is similar to Gefitinib in potency against L858R EGFR, but about 100-fold more active against the Gefitinib resistant L858R-T790M EGFR double mutant. BIBW2992 exhibits potent effects on both EGFR and HER2 phosphorylation in vivo. It compares favorably to reference compounds (such as Lapatinib et al.) in all cell types tested, such as human epidermoid carcinoma cell line A431 expressing wt EGFR, murine NIH-3T3 cells transfected with wt HER2, as well as breast cancer cell line BT-474 and gastric cancer cell line NCI-N87, which express endogenous HER2. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
HDLM-2	M4foNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1n0TWlEPTB;MD6wNFU4OiEQvF2=	NXzucFA1W0GQR1XS
KASUMI-1	M13kPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU[2SlBZUUN3ME2wMlAxQTFzIN88US=>	NYTnRlJPW0GQR1XS
HCC2218	M3rCSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMEC5PFch\|ryP	NXL2Z4xbW0GQR1XS
KARPAS-45	M4HwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXS5XIVRUUN3ME2wMlAyPjdzIN88US=>	M4j5eHNCVkeHUh?=
HSC-4	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnX5TWM2OD1yLkCxO\|Q5KM7:TR?=	MkKwV2FPT0WU
CHL-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHTd4s1UUN3ME2wMlAyQDN7IN88US=>	NFvodXJUSU6JRWK=
KY821	NHTuXY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTBwMEKwOkDPxE1?	M2PVcHNCVkeHUh?=
NCI-N87	NGTIN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfINY1KSzVyPUCuNFI4PzNizszN	MXLTRW5ITVJ?
DOK	NGXa[YVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTBwMEOxPVQh\|ryP	M1jHVnNCVkeHUh?=
DSH1	NXjNNXB7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2[4VGlEPTB;MD6wN\|MyPCEQvF2=	NIHkVWJUSU6JRWK=
MDA-MB-175-VII	M1OzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYj3TXM2UUN3ME2wMlA{PDF4IN88US=>	M4XNdnNCVkeHUh?=
NCI-H2170	M3XETWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwMEO3Nlgh\|ryP	MU\TRW5ITVJ?
BT-474	NITERnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MluyTWM2OD1yLkC0PVg3KM7:TR?=	NIO5NZRUSU6JRWK=
EFO-27	NVnjcVFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoO2TWM2OD1yLkC1NVgzKM7:TR?=	NHjiW2xUSU6JRWK=
NCI-H720	Mlj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV3JR\|UxRTBwMEWzNlUh\|ryP	NU\zOINPW0GQR1XS
PC-14	NGmwXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfYTY9PUUN3ME2wMlA2PjZ6IN88US=>	NICxZmJUSU6JRWK=
EC-GI-10	NYrT[FE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jzOWlEPTB;MD6wOVkyOiEQvF2=	NFfLfXBUSU6JRWK=
KYSE-450	NGPk[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zrd2lEPTB;MD6wOVk4QCEQvF2=	MVHTRW5ITVJ?
BPH-1	MnflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfzR\|ZKSzVyPUCuNFU6QDhizszN	NGG1TJJUSU6JRWK=
NCI-H292	NGKzflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTBwME[wPUDPxE1?	NIL2TYpUSU6JRWK=
H9	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwMEexN\|Ih\|ryP	NET6PI1USU6JRWK=
NCI-H526	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkXLTWM2OD1yLkC3PFI{KM7:TR?=	M3LSOHNCVkeHUh?=
NCI-H1623	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHOc5I3UUN3ME2wMlA5ODJ3IN88US=>	NXTsT2J4W0GQR1XS
KYSE-140	NWDCTFZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWLJR\|UxRTBwMEizN{DPxE1?	NHfnUm1USU6JRWK=
Ca9-22	MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwMEizOVMh\|ryP	NIj2RnRUSU6JRWK=
AU565	NG[1WJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTBwMEi1NFQh\|ryP	NGLsWGRUSU6JRWK=
ZR-75-30	NHHrPHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmX3TWM2OD1yLkC5OVQ2KM7:TR?=	MkHBV2FPT0WU
NCI-H1770	M4GzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX\JR\|UxRTBwMUCyPEDPxE1?	NXHxcYdEW0GQR1XS
LB2241-RCC	M3jRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXYbmZZUUN3ME2wMlExQDh2IN88US=>	MUjTRW5ITVJ?
CAL-39	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Gzd2lEPTB;MD6xNVc6OiEQvF2=	MnzZV2FPT0WU
UACC-893	M3zTTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fLWWlEPTB;MD6xNVg5PSEQvF2=	NEf0fZpUSU6JRWK=
LU-65	M{HC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnXUVJKSzVyPUCuNVI3OzNizszN	MVPTRW5ITVJ?
HN	MnHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\xTWM2OD1yLkGzNFc4KM7:TR?=	NUXzNHdUW0GQR1XS
TI-73	M3j2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYG1PVE5UUN3ME2wMlE1PzF3IN88US=>	MYDTRW5ITVJ?
KU812	NXTmfJU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrFT2RKSzVyPUCuNVU1PTZizszN	NISxc4hUSU6JRWK=
SW13	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTJVWo3UUN3ME2wMlE3OjF4IN88US=>	NW[zSJpRW0GQR1XS
BB30-HNC	NVvlb4M1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXH[otKSzVyPUCuNVY2PzZizszN	MULTRW5ITVJ?
HSC-2	MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEWwUJNKSzVyPUCuNVY5OzdizszN	MVHTRW5ITVJ?
BV-173	Ml7HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvyNoN4UUN3ME2wMlE4PTl4IN88US=>	MW\TRW5ITVJ?
CAL-27	M{\WTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDkZmVKSzVyPUCuNVc3OzZizszN	NUfKdJJoW0GQR1XS
SBC-1	NWLnTpp5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPzTWM2OD1yLkG4PVU6KM7:TR?=	NUnyeG9qW0GQR1XS
CAL-33	M1zne2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIfrdZhKSzVyPUCuNlAyQDRizszN	NU\ZPWJnW0GQR1XS
NCI-H209	M3;GVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVGyOnc{UUN3ME2wMlIxPDZizszN	MUjTRW5ITVJ?
COR-L105	NV7xW\|NJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMkGwPFQh\|ryP	MoL6V2FPT0WU
HSC-3	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlWxTWM2OD1yLkKxNVk5KM7:TR?=	MVvTRW5ITVJ?
NCI-H69	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\ISWlEPTB;MD6yNVQ2OSEQvF2=	NGjLU5BUSU6JRWK=
MOLT-13	NI\jeplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTBwMkO5O\|Uh\|ryP	NX\zT21NW0GQR1XS
ML-2	M2njb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFez[5dKSzVyPUCuNlQ5ODJizszN	NG\pNFVUSU6JRWK=
IGROV-1	NUPDUVQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYLlemdJUUN3ME2wMlI2QTV{IN88US=>	M{jye3NCVkeHUh?=
TK10	M1i1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3m5dGlEPTB;MD6yOlc{QCEQvF2=	NVzqR3FVW0GQR1XS
EoL-1-cell	NWrEW4tuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoG3TWM2OD1yLkK2PFkzKM7:TR?=	NGHmSmFUSU6JRWK=
HO-1-N-1	MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlKxTWM2OD1yLkK3PFU{KM7:TR?=	NGnCXI1USU6JRWK=
BHY	NXrPOXVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPQNmV4UUN3ME2wMlI5PjV3IN88US=>	MXTTRW5ITVJ?
LU-139	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\sS41FUUN3ME2wMlMxPTFizszN	NH\ab4FUSU6JRWK=
23132-87	M2nGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVi5OHNGUUN3ME2wMlMyQTJ\|IN88US=>	M3\PUnNCVkeHUh?=
ACHN	NUXCfXVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXfJR\|UxRTBwM{G5PVQh\|ryP	MXPTRW5ITVJ?
DoTc2-4510	NFj1S4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLDTWM2OD1yLkOyNlE6KM7:TR?=	M1vzT3NCVkeHUh?=
BB65-RCC	Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwM{S1PVMh\|ryP	NIrNeXBUSU6JRWK=
HLE	NH\pR3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLITWM2OD1yLkO1NFQ3KM7:TR?=	M4T4c3NCVkeHUh?=
HCC1419	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3ra[2lEPTB;MD6zOlQxQCEQvF2=	MXfTRW5ITVJ?
A388	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHLTWM2OD1yLkO2PFU4KM7:TR?=	M2LrdnNCVkeHUh?=
NUGC-3	NFPXeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLBW2hKSzVyPUCuN\|g{PzNizszN	NVHNXmJbW0GQR1XS
KYSE-180	NXTYZZZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTBwM{mwPFkh\|ryP	NIXjZ5FUSU6JRWK=
TE-6	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTBwNECyOFYh\|ryP	MWPTRW5ITVJ?
A498	NV7ufodVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwNEC2O\|Qh\|ryP	NIDybFdUSU6JRWK=
NCI-H1648	NEnaSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnXYTWM2OD1yLkS0NVgzKM7:TR?=	MXnTRW5ITVJ?
DU-145	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2OxU2lEPTB;MD60OFg{OyEQvF2=	NVTYW4JJW0GQR1XS
CW-2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmqwTWM2OD1yLkS2PVE1KM7:TR?=	M4Tme3NCVkeHUh?=
A431	NH7aN\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzpbmxKSzVyPUCuOFgzOzNizszN	NUC3TW1PW0GQR1XS
SAS	NF7KW4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwNEizPVgh\|ryP	NGeycYRUSU6JRWK=
NCI-H2126	NHvGcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnXTWM2OD1yLkWxPVI3KM7:TR?=	NV25ZYVvW0GQR1XS
NCI-H358	Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7mTWM2OD1yLkWzNlEh\|ryP	MYnTRW5ITVJ?
FADU	M1vnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVLkeIF2UUN3ME2wMlU1PDB2IN88US=>	MmrnV2FPT0WU
ACN	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXtbG5KSzVyPUCuOVUxQTRizszN	MXjTRW5ITVJ?
HCC70	MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvsWGxKUUN3ME2wMlU4PjZzIN88US=>	MlXhV2FPT0WU
NCI-H1838	M2TDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPETWM2OD1yLk[wNlk6KM7:TR?=	Mm\VV2FPT0WU
CAL-54	M3P4U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFLlZ4RKSzVyPUCuOlE3OjFizszN	M4\iPHNCVkeHUh?=
NCI-H1975	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTBwNkG3Nlgh\|ryP	Mli0V2FPT0WU
COR-L88	MmDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTBwNkSxNVMh\|ryP	MoXsV2FPT0WU
CTV-1	NYfJbHlVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHRSpE5UUN3ME2wMlY1Ozl{IN88US=>	MX7TRW5ITVJ?
EW-18	M{TMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlv1TWM2OD1yLk[4Olk5KM7:TR?=	MX;TRW5ITVJ?
HCC1806	M4TLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHO5N4NKSzVyPUCuOlk3PjZizszN	MkDwV2FPT0WU
HuP-T4	NGXleHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLFOJJHUUN3ME2wMlY6PzZizszN	MnjWV2FPT0WU
MDA-MB-361	MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwN{K2OlIh\|ryP	NHnFV2lUSU6JRWK=
NCI-H1573	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHaeIlnUUN3ME2wMlc{PjNizszN	M4C1[3NCVkeHUh?=
KU-19-19	NHPCUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1f3OmlEPTB;MD63O\|Q3PCEQvF2=	NGTJe3ZUSU6JRWK=
COLO-678	MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HvWWlEPTB;MD64NFg{PCEQvF2=	M2DWRXNCVkeHUh?=
C-33-A	MnjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHX3eJlKSzVyPUCuPFEzQTdizszN	NU\oPFN3W0GQR1XS
Calu-3	M3S1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPZOoFKSzVyPUCuPFE1OzRizszN	MnzPV2FPT0WU
AGS	NWq5SHZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1zaemlEPTB;MD64N\|Y1QCEQvF2=	NVTqOVM2W0GQR1XS
SCC-25	NHf4UJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2fHT2lEPTB;MD64OFE4OSEQvF2=	MoX6V2FPT0WU
JVM-2	NHnJUpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFv6WGNKSzVyPUCuPFgzQTlizszN	M2fLWnNCVkeHUh?=
HCE-T	M4TaN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrZTWM2OD1yLki4OFI5KM7:TR?=	NGPnPHZUSU6JRWK=
ES4	MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoWxTWM2OD1yLkm3PFM3KM7:TR?=	MXTTRW5ITVJ?
EKVX	MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPkTWM2OD1zLkCxNFY1KM7:TR?=	MXLTRW5ITVJ?
D-542MG	MkX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWmzcFloUUN3ME2xMlAyODZ2IN88US=>	NUKyRnB7W0GQR1XS
SW1116	M{m5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLPTWM2OD1zLkCxNlg4KM7:TR?=	NXHVfmxVW0GQR1XS
5637	NEXrWGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;KNG8{UUN3ME2xMlAyPTFizszN	NXvYfFB{W0GQR1XS
HT-1376	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfJdIhKSzVyPUGuNFE2OTNizszN	NGnsUVBUSU6JRWK=
NB69	MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{nBR2lEPTB;MT6wNlk1PSEQvF2=	M1nleHNCVkeHUh?=
YKG-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHf2T5BKSzVyPUGuNFU1OTlizszN	MXHTRW5ITVJ?
EW-3	M4H5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTFwMEe4PFMh\|ryP	MlLIV2FPT0WU
GCIY	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGj5PVJKSzVyPUGuNFgyODRizszN	M2jBbnNCVkeHUh?=
SK-MES-1	MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnDRW97UUN3ME2xMlEyPDh5IN88US=>	NVXQZWw6W0GQR1XS
PANC-08-13	NXHVSoNlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjLdppOUUN3ME2xMlE3PDF4IN88US=>	MoPHV2FPT0WU
SK-NEP-1	MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTFwMUe1NVMh\|ryP	NGfNfnJUSU6JRWK=
SW954	NYnsT21uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoC3TWM2OD1zLkKwNlE1KM7:TR?=	M2HTcHNCVkeHUh?=
NCI-SNU-5	NH7wRphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DUOmlEPTB;MT6yN\|kh\|ryP	NYT5d5RXW0GQR1XS
SW48	NGDVTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\4TWM2OD1zLkK1OFMzKM7:TR?=	M1:2b3NCVkeHUh?=
HT-3	NX;IbY1FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXJfFN7UUN3ME2xMlI5PzV\|IN88US=>	MVvTRW5ITVJ?
ETK-1	MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2PrW2lEPTB;MT6zO\|Q2PiEQvF2=	MlzVV2FPT0WU
SCC-15	NIHvcmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37ZeWlEPTB;MT6zPVQ2OSEQvF2=	MlL6V2FPT0WU
DU-4475	NUi5fFBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzDTWM2OD1zLkSwNVIyKM7:TR?=	NGnRbnlUSU6JRWK=
NB5	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnBfYtKSzVyPUGuOFE{OTdizszN	NETj[IpUSU6JRWK=
CFPAC-1	MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPNWXhKSzVyPUGuOFI1QTNizszN	NWnUeJQ4W0GQR1XS
NCI-H630	NX7he4ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTFwNEW1PFIh\|ryP	M3jaNHNCVkeHUh?=
NCI-H82	NGD6dVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\ZdmlEPTB;MT61OFAxPiEQvF2=	NWrJZ3dsW0GQR1XS
ECC10	NXHJfVhFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TK[2lEPTB;MT61OVM3QSEQvF2=	Mn3iV2FPT0WU
K5	M{LMTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jmbGlEPTB;MT61PFM2PyEQvF2=	MX\TRW5ITVJ?
ME-180	M1XYR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NInG[ZZKSzVyPUGuOlExQTZizszN	NVHqV4tNW0GQR1XS
KYSE-410	NFTiUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnER4hKSzVyPUGuOlU3PzJizszN	MYHTRW5ITVJ?
G-401	Mk\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUL4THVEUUN3ME2xMlY4PDF\|IN88US=>	NXvrb4x6W0GQR1XS
TGBC24TKB	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPnUGhKSzVyPUGuOlgzOyEQvF2=	M4LCZ3NCVkeHUh?=
Detroit562	Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUDJR\|UxRTFwN{CxOVIh\|ryP	M2LQUnNCVkeHUh?=
OE19	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3zOUGlEPTB;MT63NVUyOiEQvF2=	MW\TRW5ITVJ?
CAKI-1	NVnyXGlDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGGzUVhKSzVyPUGuO\|gzOTFizszN	NVLzd4twW0GQR1XS
TE-12	NEDQNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV[1W5I{UUN3ME2xMlgxPDF2IN88US=>	MkjVV2FPT0WU
NCI-H1666	NYDURnc4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnNTWM2OD1zLkiwPVQ5KM7:TR?=	NFPMV2tUSU6JRWK=
TE-1	MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrkXnduUUN3ME2xMlgyPDd3IN88US=>	MnjxV2FPT0WU
CAL-12T	M4LUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\KTWM2OD1zLki4PVQ2KM7:TR?=	MknKV2FPT0WU
TE-8	NVXhUVlWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGn1T29KSzVyPUGuPVE{PzdizszN	NXrqfGc{W0GQR1XS
KYSE-270	NWPHXJRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHl[5p7UUN3ME2yMlAzPzN{IN88US=>	MUnTRW5ITVJ?
GMS-10	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHWySVNKSzVyPUKuNFM2OTdizszN	NGHTTYZUSU6JRWK=
A2780	NWLhe5JPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTxbI5jUUN3ME2yMlA3Ojl2IN88US=>	NHzIfI5USU6JRWK=
OMC-1	NIC1b\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVKwWJF{UUN3ME2yMlA5OTZ7IN88US=>	MVjTRW5ITVJ?
LoVo	MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\Be5FUUUN3ME2yMlExPzl5IN88US=>	NGLmUIVUSU6JRWK=
PANC-03-27	MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX3WZVVqUUN3ME2yMlE3PjNzIN88US=>	NX3tbVlbW0GQR1XS
MDA-MB-157	M33tT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnzTWM2OD1{LkKxPFI5KM7:TR?=	NHzoXnFUSU6JRWK=
CaR-1	MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFi4dmZKSzVyPUKuNlgzQDFizszN	NXPSU5NlW0GQR1XS
769-P	NHfFW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;JUlVKSzVyPUKuNlkxOzdizszN	NI\pUlFUSU6JRWK=
NB7	NUD2ZoJ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEP0[WlKSzVyPUKuNlk3PzZizszN	MmLpV2FPT0WU
MKN7	NWjwO5I{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPOTWM2OD1{LkO1N\|M2KM7:TR?=	MmDFV2FPT0WU
NCI-H1048	M1TTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWjNTYhUUUN3ME2yMlQ6OTV6IN88US=>	NFK5Um9USU6JRWK=
RCM-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIHFenhKSzVyPUKuOVI6OzhizszN	MkLXV2FPT0WU
HT55	M4fFRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnKwTWM2OD1{LkW3N\|gh\|ryP	MkHYV2FPT0WU
HCC1569	NUKxSIgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTJwNUiyPVch\|ryP	Mmj2V2FPT0WU
LXF-289	NUjQTWJzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEC1[nJKSzVyPUKuOlM2PjVizszN	M17rcnNCVkeHUh?=
OVCAR-3	NV3SU3FRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnxV\|R6UUN3ME2yMlY4OTZ5IN88US=>	MnLHV2FPT0WU
TE-10	NIHkeJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTJwNkiwO\|gh\|ryP	NX[xfG9TW0GQR1XS
SNU-C2B	NV\YN5dkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHJTWM2OD1{Lk[4OlE3KM7:TR?=	NY\meIxbW0GQR1XS
LB1047-RCC	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnnVTWM2OD1{Lke0PFg5KM7:TR?=	M2TOUXNCVkeHUh?=
SN12C	NVrQeGVmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjU[2VKSzVyPUKuPVE6PjRizszN	MV3TRW5ITVJ?
786-0	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHTENYVKSzVyPUOuNFY1ODhizszN	MYDTRW5ITVJ?
HT-29	NUXKcJJJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYr6cI1JUUN3ME2zMlA4OzB7IN88US=>	NGrtV4ZUSU6JRWK=
RPMI-7951	M2PPNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;oSoRKSzVyPUOuNFc2QSEQvF2=	NFTFeWVUSU6JRWK=
NBsusSR	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHrTG1wUUN3ME2zMlE5OjV2IN88US=>	NVLo[IRrW0GQR1XS
NKM-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3q4XmlEPTB;Mz6xPFc1PCEQvF2=	Mlr3V2FPT0WU
Capan-2	NFGxR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvZV\|lVUUN3ME2zMlQ3QDd3IN88US=>	Mn:1V2FPT0WU
MKN1	NGTGZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfkbJRKSzVyPUOuOFcyODhizszN	NILSSYhUSU6JRWK=
OAW-42	MkKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnkW4FKSzVyPUOuOVAxOjZizszN	NXjBbXpIW0GQR1XS
SKG-IIIa	NVHlVlBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInNVnNKSzVyPUOuOVIzOzdizszN	M1LQcnNCVkeHUh?=
no-11	NGXXVo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTNwNUO1OlQh\|ryP	M4jGUXNCVkeHUh?=
NY	MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH7SW41KSzVyPUOuOVM3PTVizszN	NFHMSFlUSU6JRWK=
HEC-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml64TWM2OD1\|LkW4PVUh\|ryP	MVHTRW5ITVJ?
NCI-H441	M3;vfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTNwNUm4OFEh\|ryP	NEKwU3dUSU6JRWK=
NCI-H2009	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTNwNkGyNVYh\|ryP	MX7TRW5ITVJ?
T47D	MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTNwNkKyNVch\|ryP	NUnZdVhSW0GQR1XS
SNU-449	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTNwNkW4NlYh\|ryP	MmKxV2FPT0WU
NCI-SNU-1	MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4q0fWlEPTB;Mz62PVc{PSEQvF2=	MU\TRW5ITVJ?
BT-20	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrvTWM2OD1\|Lk[5O\|k2KM7:TR?=	NFjzTXlUSU6JRWK=
LS-123	NFfa[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DHZWlEPTB;Mz63OFI5PCEQvF2=	NGLpNYpUSU6JRWK=
8305C	M4rTcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M335eGlEPTB;Mz63OVkyOSEQvF2=	MXXTRW5ITVJ?
OCUB-M	Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTNwN{[xPFch\|ryP	NX\YSpp{W0GQR1XS
KOSC-2	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXjUG5KSzVyPUOuPFM1PTFizszN	NXLyd29oW0GQR1XS
NCI-H1693	NW\EOJhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTNwOESxPFEh\|ryP	M3;hcnNCVkeHUh?=
TE-9	NIP5RY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjld\|lWUUN3ME2zMlg1Ozh{IN88US=>	MnLVV2FPT0WU
MV-4-11	NGiyOIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTNwOEe5PVQh\|ryP	M3rzcHNCVkeHUh?=
GAMG	NV;aWVNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYTXOnV7UUN3ME2zMlkyOzF2IN88US=>	NYX6cmpEW0GQR1XS
KNS-62	NFHRZo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4SyN2lEPTB;Mz65OFc{OSEQvF2=	NWrxfVNxW0GQR1XS
MC116	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWjsW2RnUUN3ME2zMlk2PDh7IN88US=>	M37X[3NCVkeHUh?=
647-V	MnfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\pTWM2OD1\|Lkm4OFUzKM7:TR?=	MXTTRW5ITVJ?
U-87-MG	MlOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYnPXWRKUUN3ME20MlExPDhzIN88US=>	NVPTU\|R[W0GQR1XS
RPMI-8226	NH\tR5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnvR4FKSzVyPUSuNVE3OzFizszN	NFLmVYtUSU6JRWK=
SW1417	NWXocnVFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTRwMUKxOFch\|ryP	M1jSe3NCVkeHUh?=
LAMA-84	M{LRXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3m2e2lEPTB;ND6xO\|AzKM7:TR?=	NYnZRVFOW0GQR1XS
LS-513	NYf1enhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXvbIVKSzVyPUSuN\|EzOTdizszN	NYPZUG5vW0GQR1XS
KLE	MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml;WTWM2OD12LkSwPFE6KM7:TR?=	M4LMfnNCVkeHUh?=
HCT-116	NUnPNGRzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XEXWlEPTB;ND60NVAxPyEQvF2=	MV3TRW5ITVJ?
EPLC-272H	M{PRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWPJPFI6UUN3ME20MlQyPTN\|IN88US=>	M4fzZXNCVkeHUh?=
KS-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NITkcJBKSzVyPUSuOVA5QDlizszN	M1v2RXNCVkeHUh?=
HT-1197	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLQOFhKSzVyPUSuOVI3PjlizszN	M{fvbXNCVkeHUh?=
LCLC-97TM1	NE\tUG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTRwNUO2PFYh\|ryP	NGizU5dUSU6JRWK=
ES5	MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;rTWM2OD12LkizO\|I{KM7:TR?=	MoTnV2FPT0WU
CTB-1	NEXBNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETnR2ZKSzVyPUSuPFQ5QCEQvF2=	NY\zTWt2W0GQR1XS
HL-60	Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPZSGY4UUN3ME20Mlg3PjFzIN88US=>	NV7VNYdMW0GQR1XS
VM-CUB-1	Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX\JR\|UxRTRwOE[4NVkh\|ryP	NUXDTohMW0GQR1XS
MEG-01	M1vrUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTRwOUm0NFMh\|ryP	MoW0V2FPT0WU
KYSE-520	NHnyTmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTVwMkC4N\|kh\|ryP	NITCdmhUSU6JRWK=
HuO-3N1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TQV2lEPTB;NT6yOFA1OyEQvF2=	M1\ue3NCVkeHUh?=
SW620	M1HKR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XsfWlEPTB;NT6yOFk3PCEQvF2=	MXPTRW5ITVJ?
U031	NGnNbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLZVY9KSzVyPUWuNlU1OjRizszN	NVLiTpdYW0GQR1XS
TE-5	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvFTWM2OD13LkSwPFUh\|ryP	NVjYZ2hWW0GQR1XS
NCI-H747	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLvNZhCUUN3ME21MlQzPDd{IN88US=>	NUPpcFdFW0GQR1XS
MG-63	NHvZempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlTSTWM2OD13LkS4O\|YzKM7:TR?=	NV\LTHdEW0GQR1XS
HC-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NW[wbHd3UUN3ME21MlUyQDN7IN88US=>	NHPkPWxUSU6JRWK=
HCC2998	M2q2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXXJR\|UxRTVwNUK2NVUh\|ryP	MVjTRW5ITVJ?
NTERA-S-cl-D1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTVwNUS1N\|ch\|ryP	NULybHdGW0GQR1XS
KINGS-1	NF75VpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MorRTWM2OD13Lk[wPVQ1KM7:TR?=	M1:w[3NCVkeHUh?=
D-423MG	NGK3SoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXi1WGF5UUN3ME21MlYyPzB3IN88US=>	MnPIV2FPT0WU
SW962	Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfCTWM2OD13Lk[yNFMzKM7:TR?=	M1jqXnNCVkeHUh?=
LOXIMVI	M{TkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPMeldIUUN3ME21MlY{QDd\|IN88US=>	NWP0RoRKW0GQR1XS
LS-411N	NUj5XnVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2C0cGlEPTB;NT63PVQ1OSEQvF2=	MkHoV2FPT0WU
NCI-H2291	M1WyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXXc\|ZjUUN3ME21Mlk5QTR\|IN88US=>	NHS4UpFUSU6JRWK=
A549	NFjrOotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjVe3kyUUN3ME22MlEzPTV\|IN88US=>	NW[zPXRzW0GQR1XS
LS-1034	M4fSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUT6TXFmUUN3ME22MlIxPzB4IN88US=>	MX7TRW5ITVJ?
NB14	NIXINoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTZwNEO4N\|Yh\|ryP	NHPMVoVUSU6JRWK=
NCI-H1299	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXZ[pFKSzVyPU[uOlMyPzFizszN	NEnoTHlUSU6JRWK=
BT-549	Mkf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLQTWM2OD14Lk[2PFg6KM7:TR?=	NX7KWJo6W0GQR1XS
J-RT3-T3-5	NEfyXmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTZwOE[5JO69VQ>?	M{XQb3NCVkeHUh?=
SW756	NWflVmRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVriVHd2UUN3ME22MlkyOTd4IN88US=>	NF;pXnRUSU6JRWK=
DJM-1	M2rqfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTZwOUKwNVIh\|ryP	NGjhXlVUSU6JRWK=
GP5d	M1\3Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTZwOUezPVQh\|ryP	MUTTRW5ITVJ?
MOLT-4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoW1TWM2OD15LkCyNVM2KM7:TR?=	MojZV2FPT0WU
NCI-H28	NIm1VFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnN[ZY{UUN3ME23MlE3PDB3IN88US=>	NHrFNlhUSU6JRWK=
MN-60	Mn3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nSNmlEPTB;Nz6yPFA5QSEQvF2=	NFi2T\|FUSU6JRWK=
RMG-I	NHrYdWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTdwM{myPVYh\|ryP	NVnzVG8xW0GQR1XS
COLO-800	NU\J[FdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moj2TWM2OD15LkSxOFQ3KM7:TR?=	NX3B[lc{W0GQR1XS
DB	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHW5WmJKSzVyPUeuOlExODVizszN	NV\Q[4R2W0GQR1XS
Ca-Ski	M3nUOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTdwNkSyOVkh\|ryP	MnXqV2FPT0WU
HEL	NFrZcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXaXItKSzVyPUeuO\|EzODNizszN	M3S2XnNCVkeHUh?=
NH-12	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jrdmlEPTB;Nz63NlgxQCEQvF2=	MmLzV2FPT0WU
LB373-MEL-D	NFm5VYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIHIcXRKSzVyPUeuO\|Y4PzFizszN	NYHGUoQyW0GQR1XS
SW900	M1;KdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoSxTWM2OD15LkiyNVIyKM7:TR?=	M{TpUXNCVkeHUh?=
JVM-3	NGPHV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTdwOEm1PVkh\|ryP	NGHtdGVUSU6JRWK=
OAW-28	M3LuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvtcGFKSzVyPUeuPVQ2PzhizszN	MUnTRW5ITVJ?
KURAMOCHI	M2PvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTdwOUS4NVEh\|ryP	NITxWJJUSU6JRWK=
BE-13	NWfaeZdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPJTWM2OD15Lkm4NVEzKM7:TR?=	M4jOVXNCVkeHUh?=
VMRC-RCZ	NIfVfVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rnXGlEPTB;OD6wNVY6PyEQvF2=	MnXxV2FPT0WU
NCI-H727	MlzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rjSmlEPTB;OD6xNFQzKM7:TR?=	Mmj3V2FPT0WU
SW1710	M1H2bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIe4bZlKSzVyPUiuNVg2OTVizszN	M3\UdXNCVkeHUh?=
D-502MG	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTDUpVLUUN3ME24MlI6Ojh{IN88US=>	Mn;JV2FPT0WU
NCI-H1993	MmrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGXGcWFKSzVyPUiuN\|M3OzFizszN	M{K1OHNCVkeHUh?=
SCC-4	NHPaPJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXzJR\|UxRThwNESwOVkh\|ryP	M2XETnNCVkeHUh?=
HAL-01	M3yxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn36TWM2OD16LkWxPVEh\|ryP	NHvmVIdUSU6JRWK=
GT3TKB	M{DSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjEeYF6UUN3ME24MlY4QTZ2IN88US=>	MXTTRW5ITVJ?
SK-OV-3	MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TacGlEPTB;OD63NVMzQSEQvF2=	M1vwS3NCVkeHUh?=
COLO-829	NWfjNWRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRThwOEC5O\|Yh\|ryP	NYHifINTW0GQR1XS
OCI-AML2	NEjUUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLEW3d1UUN3ME24Mlk2PDhzIN88US=>	MoqwV2FPT0WU
OS-RC-2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXGe49KSzVyPUmuNFIyQSEQvF2=	M{PyNHNCVkeHUh?=
BFTC-909	NWXHUlFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVq5eYcyUUN3ME25MlA3Pzl7IN88US=>	NVPIfJhuW0GQR1XS
EW-11	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTlwMUe2OVMh\|ryP	NF7ibopUSU6JRWK=
HCE-4	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTlwMkG1OVgh\|ryP	MlHBV2FPT0WU
BALL-1	NEflVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWHKTXFyUUN3ME25MlIyQTB5IN88US=>	MVvTRW5ITVJ?
SF539	MkH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33UV2lEPTB;OT6yN\|U3OiEQvF2=	NYLwOGVyW0GQR1XS
CAMA-1	MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnSxTWM2OD17LkK4NVI5KM7:TR?=	MmH3V2FPT0WU
C32	Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;ZTWM2OD17LkOzNFY1KM7:TR?=	MWfTRW5ITVJ?
NCI-H1703	M3L5cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXtOo5KSzVyPUmuN\|Q{PzVizszN	NWPRXG9HW0GQR1XS
NCI-H1650	NF;SdFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYrwW2NYUUN3ME25MlYxQTR4IN88US=>	NV76[nF2W0GQR1XS
NCI-H1563	M2K0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHmboJ3UUN3ME25Mlc3ODNzIN88US=>	NHfQemxUSU6JRWK=
CAL-85-1	NFrFSY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGe3XoNKSzVyPUmuPFc{QDNizszN	NYPWZlZlW0GQR1XS
UM-UC-3	NUj1eGhxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHLKdW9KSzVyPUmuPVUxOyEQvF2=	MXLTRW5ITVJ?
BxPC-3	MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUO3NHZKUUN3ME2xNE4xQTd{IN88US=>	M17nb3NCVkeHUh?=
MHH-PREB-1	Mn61S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlThTWM2OD1zMD6xPVk6KM7:TR?=	NHjDeJNUSU6JRWK=
DEL	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTFyLkO5OFYh\|ryP	NHLtXopUSU6JRWK=
HuCCT1	NXLle\|drT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHqVVdpUUN3ME2xNE43ODN\|IN88US=>	MUjTRW5ITVJ?
OVCAR-4	M4nyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDrdlU1UUN3ME2xNE45QDN3IN88US=>	NHX3RlJUSU6JRWK=
CAL-72	M{TDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LFOGlEPTB;MUCuPVM6OSEQvF2=	NFrobJVUSU6JRWK=
HCC1954	MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LnW2lEPTB;MUGuNFc2PCEQvF2=	NWLCdmlJW0GQR1XS
EFO-21	NVX5NotLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTFzLkGwOFUh\|ryP	NFP6e45USU6JRWK=
FTC-133	NITCZ\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXJeo5KSzVyPUGxMlE1ODdizszN	NYjLU2xUW0GQR1XS
SK-MEL-24	M2jFc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmXTTWM2OD1zMT6yN\|Y3KM7:TR?=	MWTTRW5ITVJ?
UACC-62	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mor2TWM2OD1zMT6yN\|Y5KM7:TR?=	NFvITnlUSU6JRWK=
NCI-H650	MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTFzLkK0NVgh\|ryP	NFHRTWJUSU6JRWK=
ALL-PO	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmXFTWM2OD1zMT6yOVEzKM7:TR?=	NF71V3hUSU6JRWK=
T84	MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1eydWlEPTB;MUGuN\|kxPyEQvF2=	NI\xUXhUSU6JRWK=
IST-MEL1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmDlTWM2OD1zMT60OVU6KM7:TR?=	MX3TRW5ITVJ?
SW626	NXHBNVBjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1HsdWlEPTB;MUGuOVc2PSEQvF2=	NX\LZVQyW0GQR1XS
RPMI-2650	M3LpXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWHtd2pnUUN3ME2xNU42QDh3IN88US=>	NGXlVXVUSU6JRWK=
MC-IXC	MlvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTFzLk[3Nlgh\|ryP	M3nRN3NCVkeHUh?=
HOP-62	NV7GXXVGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfRTWM2OD1zMT62O\|Y1KM7:TR?=	NF\EOmNUSU6JRWK=
NOS-1	MnjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37DcGlEPTB;MUGuO\|ExQSEQvF2=	MWjTRW5ITVJ?
SW1573	NH\aT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXvfZhLUUN3ME2xNU44Ojl3IN88US=>	NEOxdJBUSU6JRWK=
WM-115	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFL0VYlKSzVyPUGxMlc2QDhizszN	NVe3bHdSW0GQR1XS
HuO9	NHfaWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHSxSHZKSzVyPUGxMlg4PzRizszN	NWXBRmtFW0GQR1XS
YAPC	MnHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrDPVV3UUN3ME2xNU46OjV7IN88US=>	M3q1VHNCVkeHUh?=
MDA-MB-453	Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nxR2lEPTB;MUGuPVUyPSEQvF2=	NHXkenJUSU6JRWK=
NCI-H596	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\zbGFKSzVyPUGyMlA{PjlizszN	MWXTRW5ITVJ?
A172	M4ThXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXjJR\|UxRTF{LkC3PVgh\|ryP	M{f0b3NCVkeHUh?=
RS4-11	MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fsVWlEPTB;MUKuNVczPSEQvF2=	NUDOPVRiW0GQR1XS
HCC1937	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDqN3FKSzVyPUGyMlc2PjRizszN	MYnTRW5ITVJ?
SW837	M{jGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonOTWM2OD1zMj65NFI5KM7:TR?=	NYjiOnAxW0GQR1XS
NMC-G1	NXe0RolPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TxbmlEPTB;MUKuPVI{PCEQvF2=	MW\TRW5ITVJ?
PFSK-1	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mm\uTWM2OD1zMz6wOkDPxE1?	MULTRW5ITVJ?
DBTRG-05MG	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXSdFdKSzVyPUGzMlA3OzJizszN	NVrlVmdtW0GQR1XS
SK-UT-1	MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUWzO41yUUN3ME2xN{4yODh\|IN88US=>	M{Hx[XNCVkeHUh?=
OVCAR-5	NVHDc3hYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVPPeol6UUN3ME2xN{4yPTl\|IN88US=>	MVXTRW5ITVJ?
8505C	M1jTdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrIfXNKSzVyPUGzMlIxPjdizszN	MmTFV2FPT0WU
SK-MEL-1	M2TnPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkX4TWM2OD1zMz63NVM2KM7:TR?=	MofZV2FPT0WU
LK-2	NEHJclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTF\|Lke2N\|kh\|ryP	M1qxcHNCVkeHUh?=
OE33	M{S4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkC1TWM2OD1zMz63PFYh\|ryP	Mm\NV2FPT0WU
Ramos-2G6-4C10	NWez[4ZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjhZZhkUUN3ME2xOE4xOjB{IN88US=>	MWPTRW5ITVJ?
EW-13	NFLsS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmS2TWM2OD1zND6wN\|UzKM7:TR?=	MXvTRW5ITVJ?
NCI-H1793	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTF2LkKwPFch\|ryP	NX64eJF7W0GQR1XS
BHT-101	NXm1[ZJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vTV2lEPTB;MUSuNlQyKM7:TR?=	M1mxbXNCVkeHUh?=
RKO	Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTF2LkWwO\|Uh\|ryP	M{jLcnNCVkeHUh?=
NEC8	NVn2d3JjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEXsNW9KSzVyPUG0MlU1PzJizszN	MnvCV2FPT0WU
PANC-10-05	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTF2Lk[yOFch\|ryP	NG[2cpNUSU6JRWK=
NCI-H2030	Mo\pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTF2Lk[0OFgh\|ryP	MWHTRW5ITVJ?
C2BBe1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTF2Lke2OEDPxE1?	NEW4UXdUSU6JRWK=
EM-2	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGWxO5RKSzVyPUG0Mlg2PzZizszN	M{KxPHNCVkeHUh?=
HCC1395	M1Htd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\JWGhRUUN3ME2xOE46OzN6IN88US=>	M2rNSnNCVkeHUh?=
A2058	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDYTWM2OD1zNT6wOFA6KM7:TR?=	M3nwS3NCVkeHUh?=
SW1463	NUP4NIt3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTF3LkC0PFUh\|ryP	NHnF[mVUSU6JRWK=
J82	M4jXWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fLOmlEPTB;MUWuNFU4KM7:TR?=	MUnTRW5ITVJ?
CAL-120	MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIr1b4tKSzVyPUG1MlE1PDdizszN	NWHzUXV4W0GQR1XS
COLO-824	NWfQ[3BlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHXUoxUUUN3ME2xOU4yPTd7IN88US=>	NFrzcJJUSU6JRWK=
LNCaP-Clone-FGC	NHHSdFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fpdWlEPTB;MUWuOFI1QCEQvF2=	M1jM[XNCVkeHUh?=
CP66-MEL	NX7CW3ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{j6WmlEPTB;MUWuOFY5QCEQvF2=	M1iy[nNCVkeHUh?=
OC-314	M2WwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWi2fnV{UUN3ME2xOU41PzF2IN88US=>	M4fSU3NCVkeHUh?=
OVCAR-8	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTF3Lki4OlEh\|ryP	MYLTRW5ITVJ?
MFE-280	NHTaN5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLlfm5HUUN3ME2xOk4xPDh6IN88US=>	M3XneHNCVkeHUh?=
MHH-NB-11	M{\jRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHnTWM2OD1zNj6wPFM6KM7:TR?=	NFvVXFRUSU6JRWK=
SW1990	MlXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NILwZZFKSzVyPUG2MlE4PTVizszN	M1HKR3NCVkeHUh?=
U-266	M3;XSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTF4LkKyPVkh\|ryP	NX3MSmo4W0GQR1XS
MFM-223	NYnpZWQxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPVV5BKSzVyPUG2MlM6PjVizszN	MYnTRW5ITVJ?
L-363	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHPTmRKSzVyPUG2MlQ2PzdizszN	M1W5WnNCVkeHUh?=
MCF7	NWPZRoxjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjUWZNiUUN3ME2xOk41PzJ\|IN88US=>	MX;TRW5ITVJ?
SK-MEL-3	NFzDeopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInpR2tKSzVyPUG2MlQ4QDdizszN	MYXTRW5ITVJ?
HH	NV3CNYV4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\nSWlEPTB;MU[uOVE3OiEQvF2=	M4jWT3NCVkeHUh?=
no-10	Mo[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHuOWFQUUN3ME2xOk43OzR\|IN88US=>	MkP1V2FPT0WU
HuP-T3	NVTpWVkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zwOWlEPTB;MU[uOlU4PiEQvF2=	MkPiV2FPT0WU
QIMR-WIL	NGG3Z49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzkbmJKSzVyPUG2MlcyODVizszN	NXXHPY9xW0GQR1XS
NCI-H1092	NFz2UFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTF4LkizNVYh\|ryP	MXLTRW5ITVJ?
MZ2-MEL	NHPxPHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LYfWlEPTB;MU[uPFQxOyEQvF2=	MXTTRW5ITVJ?
ES3	NYK1b2ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIe2d4ZKSzVyPUG2MlkyOzRizszN	M3zrRXNCVkeHUh?=
COLO-684	NVzvZ3pQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLrS5BXUUN3ME2xOk46PDd5IN88US=>	MVHTRW5ITVJ?
NCI-H661	Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTF4Lkm2PVQh\|ryP	M{DZN3NCVkeHUh?=
CP50-MEL-B	MkmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmXiTWM2OD1zNz6wN\|Q{KM7:TR?=	NXXoXWtiW0GQR1XS
NCI-H2405	NHnkVHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPkVIVKSzVyPUG3MlE6PzRizszN	MlGxV2FPT0WU
U-2-OS	NEX2eHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2TQVmlEPTB;MUeuOVMxPyEQvF2=	NYPDd5pRW0GQR1XS
RERF-LC-MS	M3zReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXVOHV{UUN3ME2xO{42PTB6IN88US=>	MYTTRW5ITVJ?
NCI-H2342	NVq4e2RrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnWTWM2OD1zNz61OVch\|ryP	Ml\rV2FPT0WU
ES8	NEHZV4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY[3e2c1UUN3ME2xO{43ODh5IN88US=>	NVXOUJZWW0GQR1XS
MOLT-16	NYTIXYFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTF5Lki5N\|Qh\|ryP	NIrSTWNUSU6JRWK=
RH-18	NI\5XFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\iN4VKSzVyPUG4MlAxOzVizszN	NX3GfItzW0GQR1XS
D-283MED	M{T6RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofBTWM2OD1zOD6wNFg5KM7:TR?=	MmLMV2FPT0WU
RCC10RGB	NE[0XJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTF6LkC1OVkh\|ryP	NFTBOpBUSU6JRWK=
NCI-H1437	NYrkd5VPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUDpN5RSUUN3ME2xPE4yPjRzIN88US=>	NUjaRZVXW0GQR1XS
SW982	NGfvcmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3LPOGlEPTB;MUiuNlY4OSEQvF2=	MnOyV2FPT0WU
IST-MES1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1LOZ2lEPTB;MUiuOFQzQCEQvF2=	M4jmWXNCVkeHUh?=
A704	M1PVbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnfWTWM2OD1zOD60O\|U{KM7:TR?=	NX7wcnZlW0GQR1XS
ESS-1	Ml3LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PheGlEPTB;MUiuOVIxPSEQvF2=	M3:0dnNCVkeHUh?=
SCH	NWeyNJRkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYjqe5dEUUN3ME2xPE43PDV4IN88US=>	MWHTRW5ITVJ?
COLO-320-HSR	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjRUVZKSzVyPUG4Mlc1PiEQvF2=	NXnNU4tXW0GQR1XS
Mo-T	NF64W2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HiWGlEPTB;MUiuPFIxPCEQvF2=	MVHTRW5ITVJ?
Saos-2	M2TkfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILIT5RKSzVyPUG5MlEyPjJizszN	M3LqVXNCVkeHUh?=
SW684	NWPLe3VRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvlTWM2OD1zOT6xN\|I3KM7:TR?=	NGroNo1USU6JRWK=
KMOE-2	M1jDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\RZWlEPTB;MUmuNlI1OiEQvF2=	MV;TRW5ITVJ?
MMAC-SF	NFrvS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGCzdWRKSzVyPUG5MlI3ODdizszN	MmXUV2FPT0WU
JAR	MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LwTGlEPTB;MUmuNlk6KM7:TR?=	NGHrepBUSU6JRWK=
SK-MEL-28	NWnVRWp[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYX2RpZxUUN3ME2xPU4{OzZ\|IN88US=>	M33XXHNCVkeHUh?=
KNS-81-FD	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{S1U2lEPTB;MUmuOVQ3QCEQvF2=	M4X2[3NCVkeHUh?=
ES7	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1G4dmlEPTB;MUmuOlI6OiEQvF2=	MoGwV2FPT0WU
AsPC-1	NWS0WlFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fpfmlEPTB;MUmuOlQ4OSEQvF2=	MXPTRW5ITVJ?
NCI-H1155	NHe4UVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXOxOW94UUN3ME2xPU44OjN6IN88US=>	MVfTRW5ITVJ?
KYSE-510	NETPZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3Kb4RKSzVyPUG5Mlg4PDhizszN	Mo\HV2FPT0WU
ES1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYKxeXhqUUN3ME2xPU46OjF\|IN88US=>	MUfTRW5ITVJ?
PC-3	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTF7Lkm2NFQh\|ryP	Ml\GV2FPT0WU
GCT	NUTjb416T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml:0TWM2OD1{MD6zNFI3KM7:TR?=	NX7lO5llW0GQR1XS
KARPAS-299	MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTJyLkO0NlIh\|ryP	M3LwWHNCVkeHUh?=
DOHH-2	M3PLNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\TVXVpUUN3ME2yNE42PDZ\|IN88US=>	MX7TRW5ITVJ?
COLO-741	NED4WoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fwcWlEPTB;MkCuOlYh\|ryP	MYDTRW5ITVJ?
NCI-H1395	MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWO1N5JWUUN3ME2yNE43Pjl5IN88US=>	M2DIcHNCVkeHUh?=
HCC1187	NVHnZ4E3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3GTWM2OD1{MD62O\|M1KM7:TR?=	Mmj0V2FPT0WU
Becker	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTJyLkeyNFEh\|ryP	M4\S[nNCVkeHUh?=
LU-134-A	NHH1OJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1jjUmlEPTB;MkGuNVAzPiEQvF2=	NHHsZ5lUSU6JRWK=
MKN45	NFfWNGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILBSZFKSzVyPUKxMlE2PTFizszN	M3rZUXNCVkeHUh?=
LC-2-ad	MnjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUfJR\|UxRTJzLkK3Nlkh\|ryP	M1nG[3NCVkeHUh?=
EW-24	NEDlWXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlfMTWM2OD1{MT6zPVQ2KM7:TR?=	MXzTRW5ITVJ?
SK-N-AS	M3;Tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUjR[W8zUUN3ME2yNU45Ojd4IN88US=>	MmPrV2FPT0WU
NCI-H2052	NHPqdnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\1[mlEPTB;MkGuPFk3OyEQvF2=	NUT6d2JNW0GQR1XS
A4-Fuk	NW\vNXhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnScJRKSzVyPUKyMlE1OTlizszN	NGPkbItUSU6JRWK=
NB10	NW\xVY8zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEnX[HBKSzVyPUKyMlI{PzFizszN	MkLPV2FPT0WU
CHP-212	NWHrXpVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3vQV2lEPTB;MkKuN\|IzOiEQvF2=	MmXsV2FPT0WU
KM12	NFHVNYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nJdWlEPTB;MkKuN\|U3KM7:TR?=	NVjtOnF7W0GQR1XS
JEG-3	M13Kbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rGVGlEPTB;MkKuN\|c5KM7:TR?=	M3vER3NCVkeHUh?=
LN-405	NVnaWlV1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml\WTWM2OD1{Mj61PVE{KM7:TR?=	MknlV2FPT0WU
HCT-15	NHrZVFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUH3bHZIUUN3ME2yNk44PDRzIN88US=>	MVXTRW5ITVJ?
MLMA	MnTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzUWGhMUUN3ME2yNk44PDdizszN	MXTTRW5ITVJ?
GI-1	MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3fw[2lEPTB;MkKuO\|Y2QCEQvF2=	MXTTRW5ITVJ?
RT-112	NUfvVGxCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHrTWM2OD1{Mj64OlE3KM7:TR?=	MlHEV2FPT0WU
MPP-89	MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTJ{Lki2OlEh\|ryP	NHnYb4pUSU6JRWK=
A3-KAW	M3TRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLoTWM2OD1{Mz6xNFA{KM7:TR?=	MV;TRW5ITVJ?
KALS-1	MljzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rmPWlEPTB;MkOuNVQyPCEQvF2=	MXXTRW5ITVJ?
SF126	NXnCXYxLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVK0OJpsUUN3ME2yN{43QTJ2IN88US=>	NVXRTVUyW0GQR1XS
SiHa	M1;ocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2iwNGlEPTB;MkOuPVMzPyEQvF2=	M{HLSHNCVkeHUh?=
MDA-MB-415	NUDEd\|RDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3nPWmlEPTB;MkOuPVQ6QSEQvF2=	MX\TRW5ITVJ?
Daoy	M2XnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoWyTWM2OD1{ND6xNlYh\|ryP	NFjoUYhUSU6JRWK=
COR-L23	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1H6VmlEPTB;MkSuNVc3PyEQvF2=	NYHZOGZ6W0GQR1XS
KG-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXETWM2OD1{ND6xPVI5KM7:TR?=	MV3TRW5ITVJ?
L-428	M2DZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\TVGlEPTB;MkSuOVc6OSEQvF2=	MVHTRW5ITVJ?
NCI-H520	NEPRVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HxWmlEPTB;MkSuPFg3OSEQvF2=	NHflWZNUSU6JRWK=
COLO-792	M4T5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1LyNGlEPTB;MkWuNlc{OiEQvF2=	M1\ubnNCVkeHUh?=
NB12	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTJ3LkK5OFch\|ryP	NIrnOJFUSU6JRWK=
GAK	M{LxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XoNWlEPTB;MkWuNlk3OyEQvF2=	MUnTRW5ITVJ?
SW780	NF\DSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrPbVZKSzVyPUK1MlMzPjRizszN	NEfBXWZUSU6JRWK=
GB-1	NXzkUXFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PIVWlEPTB;MkWuOFA3QSEQvF2=	MVLTRW5ITVJ?
P12-ICHIKAWA	Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULleJo5UUN3ME2yOU41Pzh3IN88US=>	MWnTRW5ITVJ?
NCI-H1651	NUi1N2xOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPCTWM2OD1{NT61PVch\|ryP	NY\pRVRLW0GQR1XS
KE-37	M2rybWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEW5fWhKSzVyPUK1Mlc{OTVizszN	M4OyfHNCVkeHUh?=
CCRF-CEM	M1j6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1H1O2lEPTB;MkWuPVY4KM7:TR?=	MUTTRW5ITVJ?
SF295	NIj4SodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm\xTWM2OD1{Nj6wOFI2KM7:TR?=	M4O2T3NCVkeHUh?=
G-361	NHfnWXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVq5NXlpUUN3ME2yOk4yODJ5IN88US=>	MYfTRW5ITVJ?
HOP-92	M1rrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{SzZ2lEPTB;Mk[uNVIzPiEQvF2=	MoG3V2FPT0WU
UMC-11	NIjP[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTJ4LkS1NVQh\|ryP	NH;GV3dUSU6JRWK=
IST-SL1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4TpcWlEPTB;Mk[uOlU6OSEQvF2=	NE\McnpUSU6JRWK=
TE-11	NWHENJJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHCTWM2OD1{Nj63O\|UzKM7:TR?=	MX\TRW5ITVJ?
NCI-H1304	NUHnSHFCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVfXS4FRUUN3ME2yOk46OTB6IN88US=>	NFSxSJZUSU6JRWK=
SJSA-1	M4DIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13aR2lEPTB;MkeuNFE4PiEQvF2=	MYfTRW5ITVJ?
BCPAP	MmDRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUTFR4R4UUN3ME2yO{4yOzdizszN	NIPMPW5USU6JRWK=
HTC-C3	NHPVfXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmn2TWM2OD1{Nz6yOVYyKM7:TR?=	NW\MdllZW0GQR1XS
EW-16	M3\QUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4TZPGlEPTB;MkeuNlk1PyEQvF2=	MkPkV2FPT0WU
HT-144	NX3hc3JiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnzV5lKSzVyPUK3MlQxOzJizszN	NXTsWIZ4W0GQR1XS
MHH-ES-1	NUewS4dIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH64NFlKSzVyPUK3MlQ1PDdizszN	NX\odJp7W0GQR1XS
T98G	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3nUllKSzVyPUK3MlU5PDZizszN	M4qxd3NCVkeHUh?=
RPMI-8866	NHf3UGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfrSVdmUUN3ME2yO{44PTZ{IN88US=>	MmLyV2FPT0WU
BEN	NYP1WY1[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzp[oY3UUN3ME2yO{45PTF5IN88US=>	M1LkNHNCVkeHUh?=
MDA-MB-231	NEDWfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY\kb2w3UUN3ME2yPE4zPzl3IN88US=>	MUHTRW5ITVJ?
HuH-7	NGXE[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonTTWM2OD1{OD60NFI5KM7:TR?=	MlL2V2FPT0WU
SK-N-FI	MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWH4doZnUUN3ME2yPE41OzNizszN	NWrTbVc1W0GQR1XS
AN3-CA	NXSwZmJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnnZYpUUUN3ME2yPE41Ozl3IN88US=>	NUnUW\|RVW0GQR1XS
EGI-1	M1nHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PiOmlEPTB;MkiuOVkzQCEQvF2=	M3LxXnNCVkeHUh?=
697	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXXKb3hYUUN3ME2yPE43OzNzIN88US=>	M{DTXXNCVkeHUh?=
TCCSUP	NF[0WJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjlWlVKSzVyPUK4MlY1OThizszN	NHPTUllUSU6JRWK=
GR-ST	M2[zdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTJ6Lk[2PVYh\|ryP	NWfQ[odEW0GQR1XS
SK-N-DZ	NW\4PYtFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;aXIRKSzVyPUK4MlY5QDVizszN	NYj3fIY6W0GQR1XS
MIA-PaCa-2	NWrrSotGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF35WZRKSzVyPUK4Mlc6PTlizszN	NF;s[pBUSU6JRWK=
IGR-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfBTWM2OD1{OD64PFc1KM7:TR?=	M4DhbnNCVkeHUh?=
BFTC-905	NEjTdJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTJ7LkK3NFUh\|ryP	MoPkV2FPT0WU
NCI-H1581	NFKxVnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPLcJRFUUN3ME2yPU4{OTR3IN88US=>	MYfTRW5ITVJ?
RD	M4\Qfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml[yTWM2OD1{OT61NlM{KM7:TR?=	NVHoNo5sW0GQR1XS
SF268	Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnsTWM2OD1{OT61PVMyKM7:TR?=	NFviUYNUSU6JRWK=
SHP-77	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2Xob2lEPTB;MkmuOlE5OiEQvF2=	Ml7CV2FPT0WU
D-566MG	Mn[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml\CTWM2OD1{OT65N\|k{KM7:TR?=	NGjD[mNUSU6JRWK=
TGBC1TKB	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HuOGlEPTB;M{CuNVI{QCEQvF2=	MWXTRW5ITVJ?
MEL-HO	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LQZ2lEPTB;M{CuNVQzOyEQvF2=	M1XifHNCVkeHUh?=
SJRH30	NWDKbHlIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1v6UGlEPTB;M{CuNlExQCEQvF2=	MnHKV2FPT0WU
D-336MG	NFu3R2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTNyLkK4PVIh\|ryP	M{\UPXNCVkeHUh?=
C3A	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPPS2FKSzVyPUOwMlI6OjdizszN	MUHTRW5ITVJ?
Calu-6	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoflTWM2OD1\|MD6yPVY{KM7:TR?=	MnL0V2FPT0WU
MZ1-PC	NYrDN3pkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLSfYdqUUN3ME2zNE4{QTNizszN	MWjTRW5ITVJ?
KYSE-70	MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HwNmlEPTB;M{CuOVEyPCEQvF2=	MYHTRW5ITVJ?
CAPAN-1	NULSO3NNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnz3TWM2OD1\|MD61NVgyKM7:TR?=	NXyxfFRtW0GQR1XS
DK-MG	M4fmNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnUSZZKSzVyPUOwMlU1PTZizszN	NEfke\|hUSU6JRWK=
SK-HEP-1	NIn6NHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInhOldKSzVyPUOwMlY{OjZizszN	NHfUTmpUSU6JRWK=
MS-1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUSwRWtxUUN3ME2zNE45QDh7IN88US=>	NYjjS4tKW0GQR1XS
GI-ME-N	M1TUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTNzLkC1O\|Eh\|ryP	NGHkbJpUSU6JRWK=
NCI-H510A	M3nmSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXhTWM2OD1\|MT60NFA3KM7:TR?=	MVfTRW5ITVJ?
NB17	Ml\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTjTWM2OD1\|MT61NVg2KM7:TR?=	NFKwPYFUSU6JRWK=
639-V	NELsSIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3FTWM2OD1\|MT61NlQ{KM7:TR?=	MYHTRW5ITVJ?
CAL-51	M3H5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DLZ2lEPTB;M{GuOVY3PyEQvF2=	MXfTRW5ITVJ?
HGC-27	NG\qTI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnQd3BKSzVyPUOxMlU5PzNizszN	NGq5bGZUSU6JRWK=
GOTO	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jnOGlEPTB;M{GuPFUxPiEQvF2=	NHP6fpJUSU6JRWK=
ChaGo-K-1	NYfwXFdvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTN{LkCwO{DPxE1?	M{LiZXNCVkeHUh?=
RO82-W-1	NHmwOnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPm[5ZKSzVyPUOyMlE3ODRizszN	MW\TRW5ITVJ?
SH-4	M3G2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnwTWM2OD1\|Mj6xPFU5KM7:TR?=	MnTxV2FPT0WU
A204	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGn2W2pKSzVyPUOyMlUxPjlizszN	NHvFWGNUSU6JRWK=
DMS-273	M3ixR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{TEOmlEPTB;M{KuOVMzOiEQvF2=	Mlm4V2FPT0WU
KGN	NFnsSFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4HHVGlEPTB;M{KuOlM{KM7:TR?=	M3TUO3NCVkeHUh?=
SK-MEL-2	NXrMO4pzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnXITWM2OD1\|Mj62OVI4KM7:TR?=	MVfTRW5ITVJ?
NCI-H2228	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYTYRVdMUUN3ME2zNk43PjB{IN88US=>	MmL2V2FPT0WU
MKN28	M1zjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTN{Lke4N\|gh\|ryP	MnzvV2FPT0WU
H-EMC-SS	MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXrJR\|UxRTN{Lkm2O\|gh\|ryP	MYPTRW5ITVJ?
ATN-1	M3rNUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUDRXIVOUUN3ME2zN{4yPDF4IN88US=>	NH36bHJUSU6JRWK=
D-263MG	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEH4cJRKSzVyPUOzMlg{PzhizszN	Ml22V2FPT0WU
LU-135	Mo\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTN\|Lki4Nlkh\|ryP	MlPuV2FPT0WU
C8166	M{jnVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVTyNFlyUUN3ME2zN{45QDV2IN88US=>	M{\yTnNCVkeHUh?=
T-24	NUDieWhqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7xZ45TUUN3ME2zOE4xOjB3IN88US=>	MkD5V2FPT0WU
Mewo	NXLnWI9KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVjJR\|UxRTN2LkGzOFkh\|ryP	NUPBWIdmW0GQR1XS
22RV1	MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;BXmJKSzVyPUO0MlE4PTRizszN	NWjyZ4NqW0GQR1XS
KM-H2	Mnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlHyTWM2OD1\|ND6xO\|c6KM7:TR?=	MUDTRW5ITVJ?
NCI-H2122	M1y2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;lbJJoUUN3ME2zOE4{PDdzIN88US=>	NVvmbIp5W0GQR1XS
ABC-1	M2qzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDRTWM2OD1\|ND6zOlk{KM7:TR?=	MV;TRW5ITVJ?
NCI-H1355	M1O3Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vjdWlEPTB;M{SuN\|g5QSEQvF2=	NU[yS\|BvW0GQR1XS
NOMO-1	Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGrGdmZKSzVyPUO0MlU4ODNizszN	M3WwdnNCVkeHUh?=
MZ7-mel	M37s[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2DMbmlEPTB;M{SuOlQ5PyEQvF2=	NXvpZmZ5W0GQR1XS
NCI-H810	M1\jVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWH2V3drUUN3ME2zOE44Ojd6IN88US=>	Mmn6V2FPT0WU
D-392MG	M4XqVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrpdY9KSzVyPUO1MlA2PjVizszN	MYXTRW5ITVJ?
LB771-HNC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIL4[GlKSzVyPUO1MlE3PThizszN	NVz1d4tIW0GQR1XS
COLO-679	NUi3XFJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3O3[GlEPTB;M{WuN\|g5KM7:TR?=	NHnZc4dUSU6JRWK=
SK-PN-DW	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\YTWM2OD1\|NT60N\|Y6KM7:TR?=	Mn2zV2FPT0WU
VA-ES-BJ	M131dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnGSnRKSzVyPUO1MlQ3PDlizszN	NF\s[WZUSU6JRWK=
KNS-42	Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlT1TWM2OD1\|NT61PFI3KM7:TR?=	M1fmZXNCVkeHUh?=
RVH-421	NYThdYYzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTN3Lke2OFUh\|ryP	M1;kN3NCVkeHUh?=
P30-OHK	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX:5fVlXUUN3ME2zOU45PzV{IN88US=>	MYHTRW5ITVJ?
G-402	Ml3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkPITWM2OD1\|NT65PFY4KM7:TR?=	Mnn6V2FPT0WU
S-117	M3;NTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3nTWM2OD1\|Nj6zNFA5KM7:TR?=	M{PoZ3NCVkeHUh?=
RXF393	M3nCOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF\YZWlKSzVyPUO2MlM4QDVizszN	Mn7VV2FPT0WU
LCLC-103H	NYTGbGZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkfXTWM2OD1\|Nj63PFA{KM7:TR?=	MVTTRW5ITVJ?
U-118-MG	MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXTrRVg6UUN3ME2zOk45QDR5IN88US=>	NWS3d2t5W0GQR1XS
8-MG-BA	NW\uPHB[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1f2ZmlEPTB;M{[uPVQ5OyEQvF2=	M4j1cXNCVkeHUh?=
MFH-ino	MnLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{iyU2lEPTB;M{euN\|M4OSEQvF2=	NH3yZlJUSU6JRWK=
NCI-H23	NWq2N\|JkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPrOoNKSzVyPUO3MlQyQTZizszN	M12yXHNCVkeHUh?=
NCI-H446	M2DaVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1X2NmlEPTB;M{euOFg3OiEQvF2=	MmXMV2FPT0WU
LU-99A	NYTTdVBMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrw[G5KSzVyPUO3MlU4OzFizszN	MWTTRW5ITVJ?
KP-N-YN	NWj6T2ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LIc2lEPTB;M{euOlE6PSEQvF2=	NGS1coRUSU6JRWK=
SCC-9	NGXOeVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYP1PWtlUUN3ME2zO{44QDN6IN88US=>	NYiybnBVW0GQR1XS
EFM-19	M17tb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zRe2lEPTB;M{euO\|k3PyEQvF2=	M1fXcHNCVkeHUh?=
A427	NE\TO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTTSIpRUUN3ME2zO{46OTB5IN88US=>	NUjX[XRLW0GQR1XS
LB831-BLC	M2LzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTN6Lk[wN\|kh\|ryP	MnPCV2FPT0WU
HOS	MkXIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFnlU\|NKSzVyPUO5MlYzPzNizszN	NX\qfHc4W0GQR1XS
LAN-6	NWXLfGtvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3y0VWlEPTB;NECuNFEyOiEQvF2=	MoLXV2FPT0WU
U251	M2nPPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTRyLkSwOVQh\|ryP	M2fGT3NCVkeHUh?=
SNU-387	M4PDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M324cWlEPTB;NECuOFU2OyEQvF2=	MXvTRW5ITVJ?
DMS-79	NGmwOpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmCxTWM2OD12MD61PFg6KM7:TR?=	M3fKUnNCVkeHUh?=
SK-LU-1	NULmO2ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnDTWM2OD12MD62OVY5KM7:TR?=	MlTQV2FPT0WU
HT	M{XpXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFvlb3RKSzVyPUSwMlY3OzlizszN	NHLxZYdUSU6JRWK=
KP-N-YS	MnzJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nVdWlEPTB;NECuOlc3QCEQvF2=	NUnOOm5bW0GQR1XS
DMS-114	NIK1bWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zBdWlEPTB;NECuPFM4PCEQvF2=	MojEV2FPT0WU
HUTU-80	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTKTWM2OD12MT6wOVY6KM7:TR?=	M1rqfnNCVkeHUh?=
ONS-76	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfHPGdKSzVyPUSxMlQ4ODlizszN	NUTsRYhiW0GQR1XS
A673	NVTpWJhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIi1XVRKSzVyPUSxMlUyPTdizszN	M33tR3NCVkeHUh?=
HPAF-II	MnTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3v5OWlEPTB;NEGuOlcxQSEQvF2=	NIrvR5ZUSU6JRWK=
UACC-257	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvVelFqUUN3ME20NU44OzZ7IN88US=>	M2fYRXNCVkeHUh?=
EW-22	NYXjUFFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLsNo1KSzVyPUSxMlg3QTdizszN	NHnk[HRUSU6JRWK=
NCI-H1755	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17rR2lEPTB;NEGuPFczPSEQvF2=	NG\GVm9USU6JRWK=
KYSE-150	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTR{LkG3PFIh\|ryP	MWjTRW5ITVJ?
CGTH-W-1	Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXP6R4tSUUN3ME20Nk41QTV3IN88US=>	MlLHV2FPT0WU
NB13	MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MW\JR\|UxRTR{Lk[yNVch\|ryP	MmTDV2FPT0WU
SW872	M1:w[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlH6TWM2OD12Mj62N\|MyKM7:TR?=	M13NTXNCVkeHUh?=
KP-4	M3Xxfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTR{Lki4N\|Ih\|ryP	M4\qUnNCVkeHUh?=
HCC38	NX;sd4VUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjm[2NKSzVyPUSyMlk3OThizszN	NHmyXoJUSU6JRWK=
BB49-HNC	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDMb4JKSzVyPUSzMlI{PTZizszN	MlryV2FPT0WU
CAL-62	MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fDdWlEPTB;NEOuOFAzQCEQvF2=	Mnv6V2FPT0WU
NCI-H2029	MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTR\|LkW1PFEh\|ryP	M4DnenNCVkeHUh?=
M14	NXu1XmxmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HkVmlEPTB;NESuNVM{OiEQvF2=	M3\oTnNCVkeHUh?=
COLO-680N	MkDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFKweYlKSzVyPUS0MlM{QSEQvF2=	Mn62V2FPT0WU
Hs-578-T	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrrcIdKSzVyPUS1MlAzQTRizszN	MlS0V2FPT0WU
MSTO-211H	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXX6[4Y2UUN3ME20OU46PDh{IN88US=>	MVzTRW5ITVJ?
EW-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml3OTWM2OD12NT65Olg6KM7:TR?=	NFHVWYxUSU6JRWK=
SW948	NVHzWJlLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIeyco5KSzVyPUS2MlQ1PjJizszN	MoK2V2FPT0WU
NCI-H460	NVSzWFV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml21TWM2OD12Nj61NlMh\|ryP	NW\VTZZZW0GQR1XS
CAS-1	Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLJT4lKSzVyPUS2Mlc4ODFizszN	M4LnSnNCVkeHUh?=
TGBC11TKB	NHn2Z3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrVWZFKSzVyPUS3MlE4PzdizszN	NISwWHdUSU6JRWK=
HD-MY-Z	MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37FPWlEPTB;NEiuO\|g3KM7:TR?=	NIP4UWxUSU6JRWK=
NCI-H226	Ml\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzRfVhKSzVyPUS5Mlc4QDVizszN	MYHTRW5ITVJ?
PA-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3r5dmlEPTB;NEmuPFM{PSEQvF2=	NHXMbGJUSU6JRWK=
LB2518-MEL	NIPXNFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTR7Lki3NlMh\|ryP	MnnHV2FPT0WU
A101D	MlixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzyO4VKSzVyPUS5Mlk1OjVizszN	MWLTRW5ITVJ?
NCI-H2087	M37EdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2LzdmlEPTB;NEmuPVY5OiEQvF2=	M2jhdHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	CIP2A / p-AKT / AKT / PARP; PubMed: 25537503 Oncotarget Time-dependent effects of afatinib on CIP2A, p-AKT and apoptosis-related proteins in the sensitive H358 and resistant H460 cells. Cells were exposed to 10 μM afatinib for up to 48 hours. Immunoblots were scanned and quantitated to determine the ratio of the level of CIP2A to actin. Data are mean ± SD. n = 3 for the different time intervals. p-EGFR / p-IGF1R / p-ERK / p-AKT; PubMed: 26052929 Mol Carcinog Effects of afatinib on EGFR and IGF1R Signaling Pathways. H1975 cells were treated with afatinib with various doses and cell lysates were subjected to Western blot analysis. Afatinib effectively inhibits p-EGFR and p-ERK while p-AKT was partially inhibited. IGF1R phosphorylation was increased upon afatinib treatment in H1975 cells. p-VEGFR2 / VEGFR2 / JAG1 / DLL4 / NICD1 ; PubMed: 28533486 Oncotarget HUVECs were cultured in the presence of Vatalanib (100 nM) or DBZ (10 nM) for 1 h and then treated for 15 min with rhgal-3 (37 nM) and cultured for additional 6 hrs. After this period, the total protein was isolated and the protein levels of galectin-3, NICD1, DLL4, JAG1, VEGFR2 and VEGFR2-p were assessed by Western blot. β-actin was used as a loading control.	25537503 26052929 28533486
Growth inhibition assay	Cell apoptosis; PubMed: 25537503 Oncotarget Dose-dependent effects of afatinib on apoptosis. Data are mean ± SD. n = 3 for each concentration. , p < 0.05, *, p < 0.01, vs. no afatinib. Cell viability; PubMed: 26515464 Oncotarget A. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion and L858R. The proportional cell viability is shown. B. MTS assay for Ba/F3 cells harboring EGFR exon 19 deletion+T790M and L858R+T790M. The proportional cell viability is shown. C. MTS assay for Ba/F3 cells harboring wild type EGFR. The proportional cell viability is shown. Erlotinib, afatinib, osimertinib, and rociletinib were used as EGFR-TKIs. Error bars indicate standard deviation.	25537503 26515464
Immunofluorescence	p65; PubMed: 26317651 Oncotarget Effects of different treatments on the nuclear translocation of the NF-κB subunit p65. A2780T cells were treated with 2.5 μM afatinib for 48 hours, or 10 μM PDTC for 2 hours. Subsequently, the NF-κB subunit p65 (red) was localized by immunofluorescence and a confocal microscopy. Nuclei were stained with DAPI (blue). Scale bar = 10 μM. vacuoles; PubMed: 29713246 Cancer Cell Int Autophagy activation upon treatment with Afatinib and Sorafenib was validated using immunofluorescence in order to visualize a creation of autophagosomes; ×60 magnification. DMSO treatment was used as control. Green—autophagy vacuoles; Blue—Hoechst, nuclear staining.	26317651 29713246

In vivo

Daily oral administration of BIBW2992 at 20 mg/kg for 25 days results in dramatic tumor regression with a cumulative treated/control tumor volume ratio (T/C ratio) of 2%. Reduced phosphorylation of EGFR and AKT is confirmed by immunohistochemical staining of tissue sections. Therefore, like lapatinib and neratinib, BIBW2992 is a next generation tyrosine kinase inhibitor (TKI) that inhibits human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases irreversibly. BIBW2992 is not only active against EGFR mutations targeted by first generation TKIs like Erlotinib or Gefitinib, but also against those insensitive to these standard therapies. ^[1]

Protocol

Kinase Assay: ^[1]	- Collapse In vitro kinase activity assays: The wild type tyrosine kinase domain of the human EGFR as well as that of the EGFR L858R/T790M double mutant are fused to Glutathione-S-transferase (GST), and extracted. Enzyme activity is then assayed in the presence of the inhibitor BIBW2992, serially diluted in 50% DMSO. A random polymer pEY (4:1) is used as substrate and biotinylated pEY (bio-pEY) is added as a tracer substrate. The kinase domain of HER2 is cloned using the baculovirus system and extracted similarly to that of EGFR kinase. Details of assays for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity are available in Supplementary information.
Cell Research: ^[1]	- Collapse Cell lines: NSCLC cells Concentrations: 0-10 μM Incubation Time: 1 hour Method: 1 × 10⁴ NSCLC cells are transferred into each well of a 96-well plate and cultured overnight in serum-free media for the EGFR phosphorylation assay. After addition of BIBW2992 on the next day, the plates are incubated at 37 °C for 1 hour. EGF-stimulation is done using 100 ng/mL for 10 min at room temperature. Cells are washed with ice cold PBS, extracted with 120 μL HEPEX buffer per well and shaken at room temperature for 1 hour. In all 2 × 10⁴ cells per well is used for the HER2 phosphorylation assay. Streptavidin precoated plates are coated with anti-EGFR-biotin at 1:100 dilution in blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Cell extracts is then transferred to the antibody-coated wells and incubated at room temperature for 1 hour. Extinction is measured at 450 nm. (Only for Reference)
Animal Research: ^[1]	- Collapse Animal Models: Athymic NMRI-nu/nu female mice Formulation: In 0.5% methocellulose-0.4% polysorbate-80 (Tween 80) Dosages: 20 mg/kg Administration: Oral administration (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	97 mg/mL (199.61 mM)
	Ethanol	15 mg/mL (30.86 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Afatinib (BIBW2992) SDF

Molecular Weight	485.94
Formula	C₂₄H₂₅ClFN₅O₃
CAS No.	439081-18-2
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03711422	Not yet recruiting	Drug: Afatinib	Non-small Cell Lung Cancer\|Leptomeningeal Disease\|Central Nervous System Metastases	National Cancer Centre Singapore	October 2018	Phase 1
NCT03083678	Recruiting	Drug: Afatinib	Chordoma	Leiden University Medical Center\|Chordoma Foundation\|Boehringer Ingelheim	June 21 2018	Phase 2
NCT03370770	Active not recruiting	Drug: Afatinib\|Drug: Osimertinib	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	December 28 2017	--
NCT02423525	Recruiting	Drug: Afatinib	Brain Cancer	Santosh Kesari\|Boehringer Ingelheim\|John Wayne Cancer Institute	December 2016	Phase 1
NCT02695290	Terminated	Drug: Afatinib	Carcinoma Non-Small-Cell Lung\|ErbB Receptors	Boehringer Ingelheim	March 17 2016	Phase 4
NCT02171741	Completed	Drug: BIBW 2992\|Drug: Docetaxel	Neoplasms	Boehringer Ingelheim	April 2005	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
For in vivo experiment of afatinib, we recommend 0.5% methylcellulose/0.2% Tween 80 as vehicle.

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Selective EGFR Inhibitor

Erlotinib HCl (OSI-744) : EGFR-selective, IC50=2 nM.
FDA-approved EGFR Inhibitor

Lapatinib : Approved by FDA for breast cancer.
Newest EGFR Inhibitor

CO-1686 (AVL-301) ^New : Irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFRL858R/T790M and EGFRWT, respectively.
Classic EGFR Inhibitor

WZ4002 : Mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.

Related EGFR Products

Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Phase 2.
Gefitinib (ZD1839)

Gefitinib (ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686, AVL-301)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.
AG-1478 (Tyrphostin AG-1478)

AG-1478 (Tyrphostin AG-1478) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR.

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)

Cited by 175 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Afatinib (BIBW2992) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products

Choose Your Country or Region

By Signaling Pathways

By product type

Afatinib (BIBW2992)

Cited by 175 Publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Afatinib (BIBW2992) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

EGFR Signaling Pathway Map

EGFR Inhibitors with Unique Features

Related EGFR Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)